Key result
Cell-free RNA profiling identifies distinct molecular signatures across 4 clinical Kawasaki disease subgroups.
Why the study?
The heterogeneous clinical presentation of Kawasaki disease complicates diagnosis and treatment, necessitating molecular signatures to stratify patients into subgroups for better understanding of pathogenesis.
Does plasma cell-free RNA profiling differentiate Kawasaki disease subgroups and distinguish them from other febrile illnesses?
Observational (n=189)
No
Does plasma cell-free RNA profiling differentiate Kawasaki disease subgroups and distinguish them from other febrile illnesses?
Cell-free RNA profiling can characterize Kawasaki disease subgroups at a molecular level, offering potential biomarkers for stratification and insights into pathogenesis.
Answers are grounded in this paper and cite their sources.
cfRNA profiling distinguishes molecular features of Kawasaki disease subgroups; hypothesis-generating and requires validation before clinical adoption.
Kawasaki disease is a pediatric vasculitis and the leading cause of acquired heart disease in children. The heterogeneous clinical presentation of Kawasaki disease complicates diagnosis and treatment, highlighting the need for molecular signatures to stratify patients into subgroups to better understand pathogenesis. We performed plasma cell-free RNA sequencing on samples from 98 patients diagnosed with Kawasaki disease, 86 febrile children (62 viral infection, 24 bacterial infection), and 5 healthy children. The Kawasaki disease patients were previously classified into one of four clinical subgroups using 14 clinical variables. Significant differences were observed in cell-free RNA transcript abundance, pathway enrichment scores, and cell type-of-origin fractions, including differences in hepatocyte injury, mitochondrial dysfunction, platelet activation, and developmental markers. This study demonstrates the utility of cell-free RNA to characterize Kawasaki disease subgroups at a molecular level. Cell-free RNA profiles may be used as biomarkers for Kawasaki disease stratification and offer new insight into the pathogenesis of specific KD phenotypes.
No takes yet. Share an insight, caveat, or question.
Loy et al. (2025) conducted an observational in Kawasaki disease (n=189). Kawasaki disease clinical subgroups vs. Other Kawasaki disease subgroups, febrile controls, and healthy children was evaluated on Differences in cell-free RNA transcript abundance, pathway enrichment scores, and cell type-of-origin fractions (p=<0.01). Plasma cell-free RNA profiling identified significant molecular differences among four clinical Kawasaki disease subgroups, revealing distinct signatures of hepatocyte injury, mitochondrial dysfunction, platelet activation, and developmental markers.
Synapse has enriched 10 related papers. Consider them for comparative context: